In this complex setting, it is plausible to ask whether genetic background, and especially the most validated genetic risk factor for MASLD and its severity, that is, PNPLA3 rs738409 C > G variant, can also affect the risk of extrahepatic complications. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.